Rchr
J-GLOBAL ID：201801020468534176
Update date: Apr. 12, 2024
Narikazu Boku
ボク ナリカズ | Narikazu Boku
Affiliation and department：
Job title：
Professor
Research field (1)：
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (5)：
- 2020 - 2023 Elucidation of cancer diversity mechanism by analysis of phosphorylation signal using biopsy tissue and application to precision medicine
- 2015 - 2018 Research on new related diseases and conditions of diabetes mellitus using a large-scale database of medical claims data and data from health checkups
- 2014 - 2017 Functional analysis of BRCA1 as the molecular basis of breast cancer therapy
- 2012 - 2015 Cancer therapeutic target identification by comprehensive kinase profiling
- 2011 - 2014 Research on the breast cancer chemotherapy targeting synthetic lethality caused by the factors in the DNA damage repair pathways.
Papers (389)：
-
Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, et al. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID). Cancer Medicine. 2024. 13. 7
-
Yusuke Taki, Seiji Ito, Junki Mizusawa, Masahiro Yura, Yuya Sato, Takashi Nomura, Masahiro Tsuda, Takeshi Omori, Chikara Kunisaki, Yasuhiro Choda, et al. Risk factors for abdominal surgical infectious complications after distal gastrectomy for gastric cancer: A post-hoc analysis of a randomized controlled trial (JCOG0912). European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2024. 50. 3. 107982-107982
-
Masanori Tokunaga, Nozomu Machida, Junki Mizusawa, Seiji Ito, Hiroshi Yabusaki, Motohiro Hirao, Masaya Watanabe, Hiroshi Imamura, Takahiro Kinoshita, Takushi Yasuda, et al. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2024
-
Yukinori Kurokawa, Yuichiro Doki, Ryo Kitabayashi, Takaki Yoshikawa, Takashi Nomura, Kunihiro Tsuji, Masahiro Goto, Haruhiko Cho, Jun Hihara, Naoki Hiki, et al. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2024
-
Takaki Yoshikawa, Masanori Terashima, Junki Mizusawa, Souya Nunobe, Yasunori Nishida, Takanobu Yamada, Masahide Kaji, Takashi Nomura, Shinji Hato, Yasuhiro Choda, et al. 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2023
ｍore...
MISC (209)：
-
堀内 裕介, 滝沢 耕平, 由雄 敏之, 吉田 尚弘, 矢野 友規, 三輪 洋人, 蓮池 典明, 小野 裕之, 武藤 学, 水澤 純基, et al. 未分化型成分を有する早期胃癌に対する内視鏡的粘膜下層剥離術後にeCuraC-2となる例の特徴 当グループ試験事後解析. Gastroenterological Endoscopy. 2021. 63. Suppl.2. 2059-2059
-
山口 和也, 吉田 和弘, 李 相雄, 加治 正英, 櫻本 信一, 水澤 純基, 福田 治彦, 朴 成和, 吉川 貴己, 寺島 雅典. 高齢者胃癌に対する治療の工夫 高齢者に対する病理学的Stage II/III胃癌の術後補助化学療法に関する臨床試験(JCOG1507). 日本消化器外科学会総会. 2021. 76回. WS10-1
-
山口 和也, 吉田 和弘, 李 相雄, 加治 正英, 櫻本 信一, 水澤 純基, 福田 治彦, 朴 成和, 吉川 貴己, 寺島 雅典. 高齢者胃癌に対する治療の工夫 高齢者に対する病理学的Stage II/III胃癌の術後補助化学療法に関する臨床試験(JCOG1507). 日本消化器外科学会総会. 2021. 76回. WS10-1
-
Eiji Sunami, Tetsuya Kusumoto, Mitsuyoshi Ota, Yoshiyuki Sakamoto, Kazuhiro Yoshida, Naohiro Tomita, Atsuyuki Maeda, Jin Teshima, Michio Okabe, Chihiro Tanaka, et al. S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial. Clinical colorectal cancer. 2020. 19. 1. 22-31
-
Yukiyasu Okamura, Satoru Yasukawa, Hiroto Narimatsu, Narikazu Boku, Akira Fukutomi, Masaru Konishi, Soichiro Morinaga, Hirochika Toyama, Yuji Kaneoka, Yasuhiro Shimizu, et al. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Cancer science. 2020. 111. 2. 548-560
ｍore...
Lectures and oral presentations (10)：
-
7. Randomizedphase II/III study of FLvs. FLTAX in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G
(2019)
-
6. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G
(ASCO-GI 2019)
-
5. CT image features of peritoneal metastasis and outcomes of the advanced gastric cancer patients receiving 2nd line chemotherapy
(ESMO-Asia 2018)
-
4. Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites
(2018)
-
3. Impact of ascites on the treatment of nivolumab for advanced gastric cancer patients
(2018)
ｍore...
Professional career (1)：
Return to Previous Page
